Feb 9th, 2023
'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot
AstraZeneca CEO Pascal Soriot’s efforts to rejuvenate the pharmaceutical company's pipeline of treatments are paying off, with a bet on new cancer drugs. Astra recorded better-than-expected results for 2022, and forecast another good year for 2023. Soriot spoke to Bloomberg's Anna Edwards and Mark Cudmore, in an exclusive interview.
